hrp0092rfc15.1 | Late Breaking Abstracts | ESPE2019

Preclinical Studies of Acrodysostosis Gene AAV Therapy in a Knock-In R368X PRKAR1A Mouse Model

Le Stunff Catherine , Gunes Yasemin , Mille Clémence , Bougnères Pierre

The use of recombinant adeno-associated viruses (rAAV) as safe vectors have allowed hundreds of gene therapy attempts to treat monogenic diseases not including bone genetic diseases (Gao G, Nat Rev Drug Dis 2019). To our knowledge, there has been few attempts to apply gene therapy to monogenic bone diseases, largely because most skeletal malformations are being developed during fetal life. Patients affected with acrodysostosis are known to aggravate their skeletal malformation...

hrp0092p1-213 | GH and IGFs (1) | ESPE2019

Determinants of Final Height in Patients Born Small for Gestational Age Treated with Recombinant Growth Hormone

Adler Elodie , Lambert Anne-sophie , Bouvattier Claire , Teinturier Cécile , Bougnères Pierre , Rodrigue Danielle , Rothbuhler Anya , De Boissieu Paul , Linglart Agnès

Introduction: About 15% of children born small for gestational age (SGA) do not reach final height within normal range. Recombinant human growth Hormone (rhGH) has shown to be effective in catching up growth velocity and height in children born SGA.The objective of our study is to identify the predictive factors of final height in children born SGA treated with rhGH.Materials and Methods: Monocentric, retrospective s...